Revance announces the launch of OPUL ™, the first relationship commerce platform for aesthetic practices
NASHVILLE, Tennessee – (COMMERCIAL THREAD) – Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company specializing in innovative aesthetic and therapeutic offerings, today announced the launch of OPUL ™, the first relationship commerce platform that combines seamless couture, simple and smart payment solutions, practice data analytics and enhanced customer service to drive increased consumer loyalty and retention, specially designed for aesthetic practices in the United States
Today’s aesthetics market is inundated with discounts and coupons, enticing consumers to buy prizes. The result for practices is a decrease in consumer loyalty and retention. As the latest launch of the Revance Aesthetics portfolio, OPUL ™ is the solution that replaces one-off transactions with a more valuable and profitable relationship model. Features of the early version include:
- Practice reports and analyzes: Comprehensive reports to help cosmetic practice owners and managers understand the health of their business with transaction and sales data for all products and services, not just a single brand.
- Customizable payment: Customizable payment options to enhance the consumer experience, including a full catalog concierge service with access to over 6,000 aesthetic products and services.
- Transparent and smart payments: OPUL operates as a registered payment facilitator (PayFac), allowing OPUL to offer low and transparent processing fees, which helps increase transaction value for practice, and provides traceable historical information purchases to help encourage repeat visits and consumer loyalty.
“OPUL ™ was designed to meet the important needs of today’s aesthetic practices – optimizing patient experiences and business outcomes through strong customer loyalty and relationships. With nearly 40,000 growing aesthetic practices in the United States, the industry is hungry for innovation, ”said Dustin S. Sjuts, Commercial Director of Revance. “OPUL ™ is therefore the first technological platform of the aesthetic vertical designed to transform the experience of doctors and consumers. The launch once again demonstrates Revance’s commitment to setting new standards through our products and services.
We will continue to offer the HintMD fintech platform, the fintech platform provided by Hint, Inc. upon its acquisition by Revance in July 2020, to existing HintMD customers with a gradual migration to OPUL through 2022.
For practices interested in learning more about OPUL ™ or to request a demonstration, please visit OPUL.com.
Revance is a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a highly purified botulinum toxin that does not contain components of human or animal origin. Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for injection in glabellar lines (frowning) and is seeking regulatory approval in the United States. Revance is also evaluating DaxibotulinumtoxinA for injection in the upper part of the face, including glabellar lines, forehead lines and crow’s feet, as well as in two therapeutic indications – cervical dystonia and upper limb spasticity in adults. . To accompany DaxibotulinumtoxinA for Injection, Revance has a unique portfolio of premium products and services for American aesthetic practices, including exclusive distribution rights in the United States of the RHA® collection of dermal fillers, the first and the only line of filler products approved by the FDA for dynamic correction of facial wrinkles and folds and the OPUL ™ relationship commerce platform. Revance has also partnered with Viatris (formerly Mylan NV) to develop a biosimilar to BOTOX®, which would compete in the current market for short-acting neuromodulators. Revance is committed to making a difference by transforming patient experiences. For more information or to join our team, visit us at www.revance.com.
“Revance Therapeutics” and the Revance logo are registered trademarks of Revance Therapeutics, Inc.
Resilient Hyaluronic Acid® and RHA® are registered trademarks of TEOXANE SA.
BOTOX® is a registered trademark of Allergan, Inc.
All statements in this press release that are not statements of historical fact, including statements relating to the potential benefits to the practices and patients of our drug candidates and technologies, including DaxibotulinumtoxinA for Injection, if any is approved, the RHA® collection of dermal fillers and OPUL ™; the needs of aesthetic practices; the rate and degree of commercial acceptance, opportunities and growth potential of OPUL ™; the aesthetics industry and the size and growth of the aesthetics market; the growth opportunities available to the business; our ability to set a new standard in health care; differentiation of our products and services from our competitors; development of a biosimilar to BOTOX®; and statements regarding our business strategy, timing and other objectives, plans and prospects, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and of Section 21E of the Securities Exchange Act of 1934, as amended. You should not rely on forward-looking statements as predictions of future events. While we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance, events, circumstances or achievements reflected in the forward-looking statements will ever be achieved or will occur.
Forward-looking statements are subject to risks and uncertainties which could cause actual results to differ materially from our expectations. These risks and uncertainties relate to, but are not limited to: the results, timing, costs and completion of our research and development activities and regulatory approvals, including the continued delay in FDA approval of the BLA for DaxibotulinumtoxinA for Injection for the treatment of glabellar lines, including as a result of observations made by the FDA during site inspection or for other reasons; the impact of the COVID-19 pandemic on our manufacturing operations, supply chain, end-user demand for our products, marketing efforts, business operations, clinical trials and other aspects of our company and in the market; our ability to manufacture supplies for our product candidates and to acquire supplies from the RHA® collection of dermal fillers; uncertain clinical development process; the risk that clinical trials may not be designed effectively or generate positive results or that positive results will ensure regulatory approval or commercial success; the applicability of clinical study results to actual results; the rate and degree of economic advantage, safety, efficacy, commercial and market acceptance, competition, size and growth potential of OPUL ™, the RHA® collection of fillers skin and our hollowed-out product candidates, if approved; our ability to continue to successfully market the RHA® collection of dermal fillers and OPUL ™ and our ability to successfully market DaxibotulinumtoxinA for Injection, if approved, as well as the timing and cost of marketing activities; our ability to expand our sales and marketing capabilities; the status of commercial collaborations; our ability to obtain financing for our operations; the cost and our ability to defend against product liability, intellectual property and other lawsuits; our ability to continue to obtain and maintain intellectual property protection for our drug candidates; our financial performance, including future income, expenses and capital requirements; and other risks. Detailed information regarding factors that could cause actual results to differ materially from the results expressed or implied by the statements contained in this press release can be found in our periodic filings with the Securities and Exchange Commission (SEC ), including the factors described in the section titled “Risk Factors” on our Form 10-K filed with the SEC on February 25, 2021 and including, without limitation, our Form 10-Q for the quarter ended February 30, 2021. June 2021, filed with the SEC on August 5, 2021. The forward-looking statements contained in this press release speak only as of the date hereof. We disclaim any obligation to update any forward-looking statements.